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Tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL) is a potent inducer of apoptosis in tumor
cells but not in healthy cells. Similar to CD95 ligand
(CD95L), TRAIL signaling requires ligand-receptor in-
teraction; the downstream signaling molecules, such as
Fas-associated death domain and caspase-8, also seem
similar. Using cells stably expressing TRAIL and CD95L,
we show that both TRAIL and CD95L induce apoptosis
in the rat colon carcinoma cell line CC531. The mito-
chondrial damage (loss of mitochondrial membrane po-
tential (MMP) and release of cytochrome c) observed
after co-incubation with TRAIL-expressing cells occurs
much earlier than that observed with CD95L-expressing
cells. The decrease in MMP induced by both ligands was
caspase-8-mediated; no difference in caspase-8 activa-
tion by TRAIL and CD95L was found. TRAIL, but not
CD95L, induced activation of caspase-10. bcl-2 overex-
pression could not prevent TRAIL-induced mitochon-
drial dysfunction, whereas it completely prevented
CD95L-mediated loss of MMP and cytochrome c release.
The selective effect of TRAIL on tumor cells and the
apparent inability of bcl-2 to block TRAIL-induced apo-
ptosis suggest that TRAIL may offer a lead for cancer
therapy in the future.
Cytotoxic lymphocytes employ two different strategies to kill
their targets: the granule secretory pathway and the ligand-
receptor interaction pathway. Ligands include CD95L1 (Fas
ligand/Apo-1 ligand) (1, 2), TRAIL (3, 4), tumor necrosis factor
 (5–7), and tumor necrosis factor-related weak inducer of
apoptosis (Apo-3 ligand) (8, 9), forming the tumor necrosis
factor superfamily (3, 4, 10, 11). Recombinant CD95L and
TRAIL kill implanted tumor cells after injection in test animals
(12–14). However, CD95L has severe toxic side effects, predom-
inantly in the liver (15, 16). In contrast, TRAIL appears to be
much less toxic (12, 13), whereas it is as efficient as CD95L in
killing tumor cells. Therefore, TRAIL seems more suitable for
therapeutic strategies directed against tumor cells than
CD95L.
CD95L and TRAIL bind to different receptors on the plasma
membrane of target cells. CD95L binds to CD95, which via the
adapter molecule Fas-associated death domain activates
caspase-8 (17–19). TRAIL can bind to DR4 (20) and DR5 (21),
which are also coupled to caspase-8 (and possibly caspase-10)
(22); alternatively, it can bind to the decoy receptors DcR1 (23)
and DcR2 (24), which have no death domain or a truncated
death domain, respectively.
The reason for the striking difference in toxicity after in vivo
application could be a difference in expression of the receptors
for both ligands by tumor cells as compared with nontrans-
formed cells and/or a different intracellular signaling route
after binding to the receptor. It has been described that de-
pending on the cell type, binding of CD95L can activate two
routes downstream of caspase-8 activation: type I apoptosis
signaling (direct activation of effector caspases by caspase-8
(18)) and type II apoptosis (cleavage of proapoptotic members of
the bcl-2 family, loss of mitochondrial membrane potential (25,
26), release of cytochrome c (27), and activation of caspase-9
(28, 29)). The routes downstream of TRAIL binding are less
well known. Thomas et al. (30) noted that TRAIL induces a
decrease in the mitochondrial membrane potential (m) in
human melanoma cells, whereas CD95L had no effect on the
m in these cells. Apparently, TRAIL induces type II apo-
ptosis. A similar finding was reported by Kim et al. (10) using
Jurkat, U937, and MCF-7 cells. If TRAIL predominantly in-
duces type II apoptosis, it can be expected to be inhibited by
bcl-2 overexpression. However, reports are conflicting. Thomas
et al. (30) reported total protection against TRAIL-induced
apoptosis, whereas Kim et al. (10) found that overexpression of
bcl-2 delayed but did not block apoptosis.
A systematic comparison of the intracellular routes after
CD95L or TRAIL signaling has, to our knowledge, never been
published. Because the reason for the difference in in vivo
application could also be due to intracellular differences, we
performed the present study, using CC531 cells as targets; this
cell type expresses CD95 and all four TRAIL receptors. Rather
than using recombinant proteins, we used 2PK3 cells stably
expressing either CD95L or TRAIL to induce apoptosis because
it was reported that membrane-expressed CD95L was more
efficient (31). We show that TRAIL causes a much more potent
dysfunction of the mitochondria than CD95L, whereas the ex-
tent of apoptosis was comparable. This suggests that CD95L
mainly caused type I apoptosis, whereas TRAIL induced type II
apoptosis. Inhibition of caspase-8 was sufficient to prevent
mitochondrial dysfunction in both cases. We found a striking
difference of overexpression of bcl-2 on apoptosis induction by
TRAIL and CD95L: bcl-2 could not prevent TRAIL-induced
mitochondrial dysfunction, whereas it completely blocked the
effect of CD95L. Also, in the bcl-2-overexpressing cells, mito-
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chondrial dysfunction was a caspase-8-mediated effect. We con-
clude that TRAIL and CD95L signaling trigger distinct intra-
cellular routes in CC531 cells.
EXPERIMENTAL PROCEDURES
Reagents—The caspase inhibitors zVAD-fmk, Ac-DEVD-CHO, and
Ac-IEPD-CHO were from Bachem (Bubendorf, Switzerland). Molecular
Probes (Leiden, The Netherlands) supplied calcein-AM, and propidium
iodide was purchased from Sigma. Annexin V was purchased from
Roche Molecular Biochemicals and labeled with allophycocyanin, a 652
nm fluorescent probe (Prozyme).
Antibodies—Anti-CD95, anti-DR4, and anti-bcl-2 antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-DR5
was obtained from Stressgen Biotechnologies (Victoria, Canada), and
anti-DcR1 and anti-DcR2 were obtained from Prosci Inc. (San Diego,
CA). The antibody against cytochrome c was purchased from BD
PharMingen. Dr. J. Borst (The Netherlands Cancer Institute, Amster-
dam, The Netherlands) kindly provided antibodies against FLIP and
caspase-8. All horseradish peroxidase-conjugated secondary antibodies
were obtained from Jackson Laboratories (West Grove, PA).
Cell Lines—CC531 cells were cultured in RPMI 1640 “Dutch modi-
fication” medium (Invitrogen) supplemented with 10% heat-inactivated
fetal calf serum, 100 g/ml streptomycin, 100 IU/ml penicillin, and 4
mM L-glutamine (Invitrogen). The bcl-2 transfectants, a gift from Rob
Hoetelmans (Department of Surgery, LUMC, Leiden, The Netherlands)
were cultured as described previously (32).
Mouse B-cell lymphoma 2PK3-mock, 2PK3-CD95L, and 2PK3-
mTRAIL cells (a kind gift from Hideo Yagita; Tokyo, Japan) were
cultured in RPMI 1640 medium (L-glutamine, 25 mM HEPES) (Invitro-
gen) supplemented with 10% heat-inactivated fetal calf serum, 100
g/ml streptomycin, and 100 IU/ml penicillin.
Co-incubation of 2PK3 Cells and CC531 Cells—CC531 cells and
2PK3 cells were harvested and washed twice. The CC531 cells were
labeled by incubation with 1 M calcein-AM for 15 min in culture
medium. Subsequently, these cells were washed and seeded in a 96-well
U-bottomed plate at a density of 1  105 cells/50 l/well. One million
2PK3 cells were added in a volume of 100 l. After the indicated time
period, the 96-well plate was centrifuged for 3 min at 1500 rpm at 4 °C.
The supernatant was removed, the cells were washed with 100 l of
phosphate-buffered saline, and the detached cells were transferred to a
clean plate. Next, the original plate was trypsinized for 10 min at 37 °C,
and the cells were added to the phosphate-buffered saline fraction. The
plate was centrifuged again for 3 min at 500  g at 4 °C. The cells were
suspended in 200 l of binding buffer (BB) containing 0.5 l of annexin
V (0.5 g/l) for flow cytometric analysis. The BB consisted of 10 mM
HEPES, 150 mM NaCl, 5 mM KCl, 1.0 mM MgCl26H2O, and 1.8 mM
CaCl22H2O in Milli Q water, pH 7.4.
Flow Cytometry—Flow cytometric analysis after co-incubation was
performed as described.2 Briefly, cells were incubated at 4 °C for 15 min
in annexin V-containing BB and washed twice with 200 l of BB. Next,
the cells were taken up in 200 l of BB, and 10 l of 100 M propidium
iodide (PI) was added shortly before measurement. Samples were ana-
lyzed on the FACScalibur (BD PharMingen). Target cells were selected
by gating the calcein-AM-positive cells. Viable cell are annexin V-
allophycocyanin- and PI-negative, apoptotic cells are annexin-positive
and PI-negative, and necrotic cells are annexin- and PI-positive.
Immunoblotting—Cells were lysed in TSE buffer (10 mM Tris-HCl,
250 mM sucrose, and 1 mM EGTA, pH 7.4, containing 1 mM dithiothre-
itol, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 mM sodium vanadate, 50
mM sodium fluoride, and 1 mM phenylmethylsulfonyl fluoride). The
protein concentration in the supernatant was determined using the
Bio-Rad protein assay with IgG as a standard. Twenty g of total
cellular protein was separated by SDS-PAGE and transferred to poly-
vinylidene difluoride membrane (Millipore). Blots were blocked with 5%
(w/v) nonfat dry milk in TBS-T (0.5 M NaCl, 20 mM Tris-HCl, 0.05% (v/v)
Tween 20, pH 7.4) and probed with the primary antibody. Next, blots
were incubated with secondary antibody containing horseradish perox-
idase and visualized with ECL reagent (Amersham Biosciences).
Mitochondrial Membrane Potential Measurements—To determine
the mitochondrial membrane potential of CC531 cells during co-incu-
bation with 2PK3 cells, 3  105 CC531 cells were plated on a coverglass
(Knittel Gla¨ser, Braunschweig, Germany) and cultured overnight at
37 °C in culture medium. The following day, these CC531 cells were
loaded with 5 M rhodamine-123 (Sigma-Aldrich) at 37 °C for 20 min.
During the loading of the CC531s cells, the effector cells were har-
vested, counted, and briefly incubated with 0.2 M rhodamine-123. The
excess rhodamine was removed from the CC531 cells, and 2PK3 cells
(3  106) were added while the coverglass was constantly kept at 37 °C
2 J. H. L. Velthuis, H. J. G. M. de Bont, J. P. Medema, P. J. K.
Kuppen, G. J. Mulder, and J. F. Nagelkerke, submitted for publication.
FIG. 1. Presence of CD95 and four TRAIL receptors in CC531s
cells. CC531s cells were cultured, lysed, and immunoblotted for CD95,
DR4, DR5, DcR1, and DcR2.
FIG. 2. Apoptosis in CC531s cells caused by CD95L and TRAIL.
CC531s cells were co-incubated with 2PK3-mock, 2PK3-mCD95L, or
2PK3-mTRAIL cells at an effector:target ratio of 10 for 3 h. Subse-
quently, apoptosis was determined by flow cytometry. In all additional
experiments, an effector:target ratio of 10 was used.
FIG. 3. Caspase involvement in CD95L- and TRAIL-mediated
apoptosis. A, CC531s cells were preincubated for 30 min with the
caspase inhibitors Ac-IEPD-CHO, Ac-DEVD-CHO, or zVAD-fmk. Next,
they were co-incubated with 2PK3-mock or 2PK3-mCD95L cells for 3 h,
and apoptosis was determined by flow cytometry. B, CC531s cells were
preincubated with the caspase inhibitors Ac-IEPD-CHO, z-AEVD-fmk,
the combination of Ac-IEPD-CHO and Ac-AEVD-CHO (I  A), Ac-
DEVD-CHO, or zVAD-fmk. Next, they were co-incubated with 2PK3-
mock or 2PK3-mTRAIL cells for 3 h, and apoptosis was determined by
flow cytometry. , statistically different from incubation with effector
cells solely.
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under a confocal laser scanning microscope. During a 3-h time course,
images of rhodamine-123 fluorescence were made every 2 min.
Analysis was done by selecting a single cell and making a plot of pixel
intensity versus the number of pixels. Herein, the mitochondria have a
much higher intensity than the background. By selecting a minimal
intensity, the mitochondria were separated from the background. Next,
the mean pixel intensity and the number of pixels of the mitochondria
were calculated and multiplied. These values are plotted as the per-
centage of the initial total pixel intensity versus time (min). At least five
cells were selected and quantified per experiment.
Detection of Cytochrome c Release—CC531 cells were plated on a
coverglass and allowed to attach overnight. The following day, they
were co-incubated with effector cells for the indicated period. Subse-
quently, the cells were washed twice with phosphate-buffered saline
containing 0.2% EDTA, thereby removing the effector cells but not
affecting the target cells. Attached cells were analyzed by flow cytom-
etry and proven to be 95% CC531 cells (data not shown). After sepa-
ration of the two cell types, mitochondrial and cytoplasmic fractions
were prepared from CC531 cells as described previously (33), and the
fractions were immunoblotted for cytochrome c.
Statistical Analysis—Statistical analysis was performed using Stu-
dent’s two-sample equal variance two-tailed t test.
RESULTS
Receptor Expression—A prerequisite for comparing the in-
tracellular routes leading to apoptosis after TRAIL or CD95L
exposure is the presence of CD95 and all four TRAIL receptors
on the target cell. Therefore, the expression of the receptors
was determined on CC531s, the rat colon carcinoma cell line
that we found to be sensitive toward both ligands. Immunoblots
stained for CD95 and all TRAIL receptors clearly show that all
receptors were present (Fig. 1). There seemed to be slightly
more DR5 than DR4 at the protein level. The same was true for
DcR2 as compared with DcR1. Thus, CD95 and the four TRAIL
receptors were present in the CC531s cell line which made it a
suitable target cell to investigate TRAIL and CD95L signaling.
TRAIL- and CD95L-induced Apoptosis in CC531s Cells—To
study the effect of TRAIL and CD95L signaling, we used 2PK3
cells that had been transfected with either mTRAIL or
mCD95L as effector cells, and 2PK3-mock cells served as con-
trol (34). This provided us with a tool to compare TRAIL to
CD95L using the same effector and target cell line. First, we
FIG. 4. Mitochondrial membrane
potential of CC531s cells after co-in-
cubation with 2PK3 cells. A, attached
CC531s cells were loaded with rhoda-
mine-123 and co-incubated for the indi-
cated periods with 2PK3-mock, 2PK3-
mCD95L, or 2PK3-mTRAIL cells. Every 2
min, a confocal laser scanning image was
recorded. Several time points are shown.
B, with 10-min intervals, recordings were
quantified and plotted as the percentage
of the initial value.
FIG. 5. Cytochrome c release after
TRAIL and CD95L exposure. CC531s
cells were co-incubated with 2PK3-
mTRAIL or 2PK3-mCD95L cells for the
indicated periods, and then the effector
cells were washed off. Next, the mitochon-
drial and cytosolic fractions were isolated
and immunoblotted for cytochrome c.
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determined TRAIL- and CD95L-induced apoptosis in CC531s
cells. The cells were co-incubated with effector cells at an
effector:target ratio of 10 for 3 h. Subsequently, the calcein-
AM-labeled CC531s cells were stained with annexin V and PI.
Using flow cytometry, cells positive for annexin V-allophyco-
cyanin but negative for PI were identified as apoptotic. As
shown in Fig. 2, 32% of the CC531s cells showed apoptotic
features after co-incubation with 2PK3-mTRAIL cells, whereas
co-incubation with the mock-transfected 2PK3 cell line caused
no apoptosis. 2PK3-mCD95L cells as effectors resulted in 36%
apoptotic CC531s cells.
Involvement of Caspases—The importance of caspase-8 and
-3 has been described extensively for apoptosis induced by
CD95L and to a lesser extent for that induced by TRAIL. Thus,
we assessed the role of upstream caspase-8 and -10 as well as
downstream caspase-3 by preincubation of the CC531s cells
with caspase inhibitors before the addition of the 2PK3 cells.
Inhibition of caspase-8 by Ac-IEPD-CHO, inhibition of
caspase-3 by Ac-DEVD-CHO, or inhibition of all caspases by
zVAD-fmk completely prevented CD95L-induced apoptosis
(Fig. 3A). In TRAIL-mediated apoptosis, inhibition of caspase-8
reduced the level of apoptotic CC531s cells from 33% to 15%
(Fig. 2B). Addition of zVAD-fmk as well as the combined addi-
tion of Ac-IEPD-CHO and the caspase-10 inhibitor z-AEVD-
fmk (indicated as I  A) completely prevented apoptosis. The
inhibitory effect of Ac-DEVD-CHO was very similar to single
addition of Ac-IEPD-CHO (the level of apoptotic cells was re-
duced from 33% to 15%). Addition of zAEVD-fmk only slightly
reduced apoptosis by TRAIL.
Mitochondrial Dysfunction—Both TRAIL and CD95L caused
a comparable level of apoptosis in CC531s cells. To find out
whether the intracellular signaling pathways involved were
the same, we examined whether CD95L and TRAIL signaling
caused mitochondrial dysfunction. First, the effect of 2PK3-
mTRAIL and 2PK3-mCD95L on the mitochondrial membrane
potential (m) in CC531s cells was studied. Mitochondria of
CC531s cells were loaded with rhodamine-123 to quantify m
(35) before the addition of the 2PK3-mTRAIL or 2PK3-
mCD95L cells. Subsequently, cells were monitored for 3 h
using a confocal laser scanning microscope. Co-incubation with
2PK3-mTRAIL cells rapidly decreased the m of CC531s
cells: after 60 min, the maximum rhodamine-123 release was
almost complete (Fig. 4). Co-incubation with the 2PK3-
mCD95L cell line also decreased m, but maximum rhoda-
mine-123 release was not seen until 2 h after the start of the
co-incubation. The addition of 2PK3-mock cells induced no
other than a spontaneous release of rhodamine-123.
Because both ligands induced loss of m, the release of
cytochrome c needed for the formation of the apoptosome and
activation of caspase-9 was studied. After co-incubation, the
mitochondrial and cytosolic fractions of CC531s cells were im-
FIG. 6. Caspase dependence of the loss of mitochondrial mem-
brane potential of CC531s cells. A, CC531s cells were loaded with
rhodamine-123 and pretreated with 100 M of the indicated caspase
inhibitors. Subsequently, they were co-incubated with 2PK3-mTRAIL
cells. Every 2 min, a confocal laser scanning image was recorded. With
10-min intervals, recordings of m were quantified and plotted as the
percentage of the initial value. B, as described in A, but with 2PK3-
mCD95L cells as effector cells.
FIG. 7. Caspase-8 activation after
TRAIL and CD95L signaling. A,
CC531s cells were co-incubated with
2PK3-mock, 2PK3-mTRAIL, or 2PK3-
mCD95L cells for the indicated periods,
and then the effector cells were washed
off. Next, the CC531s cells were immuno-
blotted for active caspase-8. B, immuno-
blot results from A were analyzed by
densitometry.
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munoblotted for cytochrome c. After just 15 min of 2PK3-
mTRAIL exposure, cytochrome c appeared in the cytosolic frac-
tion of the CC531s cells (Fig. 5), and the concentration
increased with time. Consequently, in mitochondria, cyto-
chrome c decreased with longer incubation periods. In contrast,
the release of cytochrome c from mitochondria was much
slower after incubation with 2PK3-mCD95L cells. Release of
cytochrome c was only fully detectable after 120 min of expo-
sure to the effector cells. No cytosolic cytochrome c was de-
tected after co-incubation with the mock-transfected 2PK3
cells.
Caspase Involvement in Mitochondrial Dysfunction—Both
TRAIL and CD95L cause mitochondrial dysfunction, although
to a different extent. In the effect of both agents, an important
role for caspase-8 was observed (Fig. 3); caspase-8 is capable of
cleaving proapoptotic members of the bcl-2 family as well as
directly activating caspase-3, which, in its turn, can cause
mitochondrial dysfunction. Therefore, we studied the effects on
m in the presence of caspase inhibitors. The effect of 2PK3-
mTRAIL cells could be fully prevented by addition of the
caspase-8 inhibitor Ac-IEPD-CHO and the pan-caspase inhib-
itor zVAD-fmk (Fig. 6A). In contrast, the presence of the
caspase-3 inhibitor Ac-DEVD-CHO had no effect on the loss of
m, indicating that loss of m was downstream of
caspase-8 but upstream of caspase-3. Addition of the
caspase-10 inhibitor z-AEVD-fmk had no effect on the loss of
m (data not shown). Like TRAIL, CD95L-induced mitochon-
drial dysfunction was prevented by the addition of Ac-IEPD-
CHO and zVAD-fmk (Fig. 6B). Again, inhibition of caspase-3
could not prevent the loss of m. Therefore, CD95L-mediated
loss of mitochondrial membrane potential was also a caspase-8
mediated phenomenon.
One possible explanation for the much more rapid decrease
of m after TRAIL in comparison with CD95L might be a
more efficient activation of caspase-8. Therefore, CC531s cells
were exposed to the effector cells for the indicated periods,
lysed, and immunoblotted for active caspase-8. No difference
was observed between TRAIL- and CD95L-induced activation
of caspase-8 (Fig. 7A). Also, densitometrical analysis of the
immunoblot revealed no difference (Fig. 7B).
Effect of bcl-2 Overexpression on TRAIL-induced Apoptosis—
Because TRAIL signaling in CC531s cells caused such a strong
decrease in mitochondrial membrane potential, the effect of
overexpression of the antiapoptotic protein bcl-2 in a stably
transfected CC531-bcl-2 cell line (32) was examined.
To confirm that bcl-2 transfection did not affect receptor
expression or the level of FLIP (an inhibitor of Fas-associated
death domain caspase-8 signaling), CC531s and CC531-bcl-2
cells were checked for the presence of the four receptors for
TRAIL as well as CD95; the level of endogenous FLIP and bcl-2
in the CC531s and CC531-bcl-2 cells was compared by immu-
noblotting (Fig. 8, S, CC531s cells; bcl-2, CC531-bcl-2 cells).
Clearly, the expression of the death receptors and the levels of
FLIP were comparable. Apparently, the difference between the
two cell lines was due only to the overexpression of bcl-2 (Fig.
8, Bcl-2).
Next we examined the effect of overexpression of bcl-2 in
CC531 cells on TRAIL- and CD95L-mediated apoptosis (Fig. 9).
TRAIL-induced apoptosis was decreased (22% versus 32% in
CC531s cells) but not prevented. The same was seen for
FIG. 8. Presence of death receptors and antiapoptotic proteins
in CC531s and CC531-bcl-2 cells. CC531s and CC531-bcl-2 cells were
immunoblotted for CD95, the four TRAIL receptors, FLIP, and bcl-2.
FIG. 9. Sensitivity of CC531-bcl-2 cells toward TRAIL and
CD95L. bcl-2-overexpressing CC531 cells were co-incubated with
2PK3-mock, 2PK3-mTRAIL, and 2PK3-mCD95L cells for 3 h. Subse-
quently, apoptosis was determined by flow cytometry. , statistically
different from the CC531s cell line.
FIG. 10. Mitochondrial membrane potential of CC531s and
CC531-bcl-2 cells after TRAIL and CD95L signaling. A, CC531s
and CC531-bcl-2 cells were loaded with rhodamine-123 and co-incu-
bated with 2PK3-mock and 2PK3-mTRAIL cells. Every 2 min, a confo-
cal laser scanning image was recorded. With 10-min intervals, record-
ings were quantified and plotted as the percentage of the initial value.
B, as described in A, but with 2PK3-mCD95L cells as effector cells.
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CD95L-mediated cell death (which decreased from 36% to
28%). Therefore, bcl-2 overexpression reduced but could not
prevent apoptosis initiated by either of the two ligands.
Because bcl-2 can protect mitochondrial dysfunction after
various stimuli, and TRAIL caused mainly type II apoptosis,
we had expected a more pronounced effect of bcl-2 overexpres-
sion on TRAIL-induced apoptosis. Therefore, we examined the
mitochondrial membrane potential of CC531-bcl-2 cells after
exposure to 2PK3-mTRAIL and 2PK3-mCD95L cells. bcl-2
overexpression slightly delayed TRAIL-induced loss of m,
but after 70 min, no difference between CC531s and CC531-
bcl-2 cells was detected any more (Fig. 10A). In contrast, bcl-2
overexpression completely prevented CD95L-induced loss of
m in these cells (Fig. 10B).
Because loss of m in CC531-bcl-2 cells after TRAIL sig-
naling was little affected, the release of cytochrome c from
bcl-2-overexpressing cells was compared with that from
CC531s cells. Similar to the loss of m, release of cytochrome
c was hardly affected by bcl-2 overexpression after TRAIL
signaling (Fig. 11A). In contrast, similar to the loss of m,
bcl-2 overexpression prevented the release of cytochrome c
after CD95L signaling (Fig. 11B).
Finally, the involvement of caspases in TRAIL-mediated mi-
tochondrial dysfunction was studied in the CC531-bcl-2 cell
line. As with standard CC531 cells, the presence of Ac-IEPD-
CHO or zVAD-fmk was sufficient to prevent the loss of m,
whereas Ac-DEVD-CHO had no protective effect. Thus, in
CC531-bcl-2 cells, mitochondrial dysfunction was also down-
stream of caspase-8 but upstream of caspase-3 (Fig. 12).
DISCUSSION
Both TRAIL and CD95L seemed equally potent in inducing
apoptosis in CC531s cells: co-incubation with 2PK3-mTRAIL or
2PK3-mCD95L cells resulted in 32% and 36% apoptotic cells,
respectively. Inhibition of caspase-8 was sufficient to abolish
CD95L-induced apoptosis, whereas TRAIL-mediated apoptosis
was largely dependent on caspase-8, but a role for caspase-10
remained: an additional inhibition from 15% to 9% was seen.
Also, inhibition of the effector caspases-3 and -7 by Ac-DEVD-
CHO prevented CD95L-initiated apoptosis but only reduced
TRAIL-mediated apoptosis. zVAD-fmk could completely pre-
vent apoptosis by both ligands. These results were similar to
the observations by Seol et al. (36), who showed that addition of
z-DEVD-fmk was not sufficient to restore cell viability in the
presence of TRAIL. In contrast, Kim et al. (10) reported that
z-DEVD-fmk prevented TRAIL-induced apoptosis. Kim et al.
(10) used Jurkat cells, whereas Seol et al. (36) used HeLa cells.
In this respect, CC531s cells resemble HeLa cells. Further-
more, TRAIL caused such a potent disruption of the mitochon-
dria (Fig. 4) that inhibition of the effector caspases-3 and -7
may simply be insufficient to prevent apoptosis because many
mitochondrial factors are already released into the cytosol.
The much earlier occurring mitochondrial dysfunction
caused by TRAIL as well as that of CD95L could be prevented
by Ac-IEPD-CHO and was therefore a caspase-8-mediated ef-
fect. However, the difference in potency in mitochondrial dys-
function between TRAIL and CD95L could not be explained by
a more efficient activation of caspase-8 (Fig. 7). Furthermore,
overexpression of bcl-2 only slightly delayed the loss of m in
TRAIL-mediated apoptosis as compared with CC531s cells,
whereas no difference was found in release of cytochrome c.
Possibly, a mitochondrial membrane-disrupting protein is ac-
tivated by TRAIL signaling that is not inhibited by bcl-2. Ap-
parently this disrupting protein is not activated by CD95L
FIG. 12. Caspase dependence of the loss of mitochondrial
membrane potential of CC531-bcl-2 cells. CC531-bcl-2 cells were
loaded with rhodamine-123 and treated with 100 M of the indicated
caspase inhibitors. Subsequently, they were co-incubated with 2PK3-
mTRAIL cells. Every 2 min, a confocal laser scanning image was re-
corded. With 10-min intervals, recordings were quantified and plotted
as the percentage of the initial value.
FIG. 11. Cytochrome c release after
TRAIL and CD95L signaling in CC531s
and CC531-bcl-2 cells. A, CC531s and
CC531-bcl-2 cells were co-incubated with
2PK3-mTRAIL cells for the indicated
periods, and then the effector cells were
washed off. Next, the mitochondrial and
cytosolic fractions were isolated and immu-
noblotted for cytochrome c. B, as described
in A, but with 2PK3-mCD95L cells.
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signaling. These results support the previous observations by
Kim et al. (10), who, after 16 h, no longer saw a difference
between bcl-2-transfected and neo-Jurkat cells in retention of
the mitochondrial dye DiOC6. Our results showed a significant
difference between the standard CC531s cell line and the bcl-
2-transfected cell line up to 1 h after the start of the co-
incubation, but not after that time point. Moreover, Keogh et al.
(37) showed that bcl-2 overexpression completely blocked UV-
induced cytochrome c release but failed to do so after TRAIL
signaling. In contrast, both Rokhlin et al. (38) and Munshi et al.
(39) reported that bcl-2 overexpression in human prostate car-
cinoma cell lines protected them against TRAIL-induced apop-
tosis. Rokhlin et al. (38) also reported that bcl-2 overexpression
abrogated the loss of m and the release of cytochrome c. One
possible explanation might be the lack of the suggested TRAIL-
activated mitochondrial disrupting protein in human prostate
cancers.
Although TRAIL-induced apoptosis is strongly dependent on
the mitochondrial route, it has been shown that some effects of
TRAIL are mediated by direct activation of caspase-3 by up-
stream caspase-8 (40). Thus, TRAIL can induce apoptosis in a
mitochondria-dependent and -independent manner (41), al-
though the mitochondrial amplification loop plays an impor-
tant role. Again, this is in contrast with the findings of Rokhlin
et al. (38) and Munshi et al. (39) because they reported the
absence of apoptosis in bcl-2-overexpressing prostate carci-
noma cells, suggesting a lack of TRAIL-induced type I apo-
ptosis in this cell type. Thus, TRAIL could be effective as a
possible future treatment for several cancers (40) such as
lymphoid and colon tumors, whereas for prostate cancer, it may
prove to be an ineffective antitumor agent.
In CC531-bcl-2 cells, the loss of m could be inhibited by
the addition of Ac-IEPD-CHO. Thus caspase-8 was also respon-
sible for the mitochondrial dysfunction in these cells. Further-
more, no delay in release of cytochrome c in CC531-bcl-2 cells
as compared with CC531s cells was detected. In comparison,
CD95L-induced cytochrome c release was prevented by bcl-2
overexpression, concordant with prevention of the loss of m
(Fig. 10B).
Taken together, the much more potent disruption of mito-
chondrial membrane potential by TRAIL as compared with
CD95L and the release of cytochrome c, both of which were
hardly inhibitable by bcl-2 overexpression but in all cases were
caspase-8-mediated, indicate distinct intracellular signaling in
TRAIL- and CD95L-mediated apoptosis.
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